No Benefit Seen for Revascularization Added to Drug Therapy in Carotid Stenosis
By Elana Gotkine HealthDay Reporter
FRIDAY, May 2, 2025 -- For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted stroke risk, there is no benefit for the addition of revascularization to optimized medical therapy (OMT) in the first two years, according to a study published in the May issue of The Lancet Neurology.
Simone J.A. Donners, M.D., from UMC Utrecht in the Netherlands, and colleagues examined whether patients with asymptomatic and symptomatic carotid stenosis with a low or intermediate predicted risk fir stroke, who received OMT, would benefit from additional revascularization in a multicenter randomized trial. Patients aged 18 years and older, with asymptomatic or symptomatic carotid stenosis of 50 percent or greater, and a five-year predicted risk for ipsilateral stroke of less than 20 percent, were randomly assigned to OMT alone or OMT plus revascularization (215 and 214 patients, respectively).
The researchers found that with respect to the primary hierarchical outcome composite of periprocedural death, fatal stroke, or fatal myocardial infarction; nonfatal stroke; nonfatal myocardial infarction; or new silent cerebral infarction on imaging assessed two years after randomization, no benefit was recorded in favor of either treatment group, with 11.4 and 11.3 percent wins for the OMT alone and OMT plus revascularization groups, and 77.3 percent ties between groups.
"We cannot rule out the possibility that revascularization will provide a small to moderate benefit in our patients beyond two years. We are, therefore, continuing follow-up to five years after randomization," the authors write.
Several authors disclosed ties to the biotechnology, publishing, and medico-legal industries.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Delirium Common Among Critically Ill Patients With Stroke
TUESDAY, July 8, 2025 -- More than one in four critically ill patients with stroke experience delirium, according to a study published online July 1 in the American Journal...
A-Fib Catheter Ablation Cuts Risk for Ischemic Stroke After 30 Days, Mortality, Heart Failure Hospitalization
MONDAY, July 7, 2025 -- For patients with atrial fibrillation, catheter ablation reduces the risks for ischemic stroke at more than 30 days, mortality, and heart failure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.